Ocular Therapeutix has received acknowledgement from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Dextenza has been received. Dextenza (dexamethasone insert) 0.4mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery. The FDA considers the NDA resubmission as a class 2 response to its July 2017 Complete Response Letter with a PDUFA (Prescription Drug User Fee Act) target date of December 28, 2018 for the completion of the FDA’s review of the Dextenza NDA.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
“We are pleased with the recent news that the FDA has formally accepted our resubmission of the Dextenza NDA,” said Antony Mattessich, President and Chief Executive Officer. “This marks one more important step towards our goal of bringing this important new treatment to the market.”